Facebook Facebook Share

Rona-story

Rona's story

"I would absolutely recommend women to take part in trials if they feel it is right for them. Certainly I was very keen to take part in it because I want to try and increase the different drugs that are available for use with ovarian cancer."

There is an urgent need for new treatments to improve survival. Without clinical trials, medical research cannot progress. Find out how we’re campaigning for better access to clinical trials.

Currently, fewer than 500 women with ovarian cancer annually enter a clinical trial aimed at finding new treatments 1. This is only seven per cent of the 7,000 women diagnosed each year, despite the Government's Life Sciences Strategy, which aims to "place clinical research at the heart of the NHS, and empower patients to participate in research" 2.

In addition, there is unequal access to clinical trials, dependent on an individual's postcode, and only 30 per cent of women are informed about clinical trials by their clinician 3.

Yet research has shown that participation in a clinical trial improves long-term survival, whether part of the control arm or the active research 4, and that those hospitals which undertake medical research provide better treatment 5.What needs to change?

What needs to change?

  • All women diagnosed with ovarian cancer must be informed about clinical trials.
  • No presumptions must be made based on age, health or distance from a trial to not inform women about clinical trials; it is their choice.
  • Women must feel empowered to ask their clinician or health professional about available clinical trials.
  • Regional variation must end: All women, irrespective of their location, have an equal right to access trials across the whole of the UK.
  • Quicker clinical trials must be set up to allow for more trials, more centres, more choice and more women in trials.
  • More resources must be provided to support the clinical community to ensure there are more trials so more potential treatments can be tested.

Our campaign so far

Watch this video from our ambassador Rona Passmore, about her experience on a clinical trial:

Help us campaign

  • Ask your clinician to tell you about clinical trials you may be eligible for. 
  • Use our Clinical Trials Information Centre to find trials either by location or keyword. Results can easily be emailed or printed out for your medical appointments
  • Contact us if you are unsure or not satisfied with the information or answers you have received
  • Ensure your health professionals have bookmarked our Clinical Trials Information Centre so next time they can provide help more quickly.
  • Share your story with us - it is the stories from people who have experienced ovarian cancer first-hand that influence change, and that inspire women or family members in similar circumstances.

Stay up to date

Visit the Clinical Trials Information Centre

References
  1. National Institute for Health Research Cancer Research Network (NCRN) 2011-12 and 2012-13 data
  2. Department for Business Innovation and Skills, Strategy for UK Life Sciences
  3. Target Ovarian Cancer Pathfinder Study 2012. Ipsos Mori. 15 Jan 2014, page 57. 
  4. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Du Bois, A.; Rochon, J; Lamparter, ; Pfisterer, J. International Journal of Gynaecological Cancer 2005 (vol 15) pp. 183-191(9)
  5. Engagement in research: an innovative three-stage review of the benefits for health-care performance. Hanney, S; Boaz, A; Jones, T; Soper B. Health Services and Delivery Research 2013 (Vol1) Issue: 8

Read related news

News
Researching the immune system to tackle ovarian cancer
Wednesday 3 June 2020
This week our immunotherapy project led by Dr Martin Miller at the University of Cambridge revealed an important new piece of the puzzle of developing more effective treatments for the most common form of ovarian cancer. The paper, published in high-profile journal Nature Genetics, has uncovered...
News
Searching new treatments for low grade serous ovarian cancer
Wednesday 29 January 2020
Target Ovarian Cancer is announcing a brand new award for research into a less common type of this disease. Our new project will find new ways to treat low grade serous ovarian cancer. Because this type of ovarian cancer affects a smaller group of women than other types (around 700 women each year...
News
Monday 9 December 2019
The Scottish Medicines Consortium (SMC) has joined the National Institute for Health and Care Excellence (NICE) by approving a breakthrough ovarian cancer drug from the first round of treatment, meaning it is now available across the UK. Olaparib (Lynparza®) is one of a new generation of drugs...
News
Donate
Friday 27 September 2019
News from the European Society of Medical Oncology (ESMO) conference means more women could be able to access innovative treatments earlier. Three announcements on the benefits of a new generation of ovarian cancer drugs, PARP inhibitors, were made over the weekend at the research conference in...

Pages